瑞舒伐他汀对急性冠脉综合征患者血清MMP-9和hs-CRP的影响

Effects of rosuvastatin on serum MMP-9and hs-CRP in patients with acute coronary syndrome

目的探讨瑞舒伐他汀对急性冠脉综合征(ACS)患者血清基质金属蛋白酶9(MMP-9)和高敏C反应蛋白(hs-CRP)的影响。方法 ACS患者60例分为口服瑞舒伐他汀10mg/d(A组,30例)、20mg/d(B组,30例)和正常对照(C组,20例)。ELISA法检测治疗前后各组间血清MMP-9和hs-CRP水平。结果治疗前A、B组血清MMP-9和hs-CRP水平均高于C组(P<0.05)。瑞舒伐他汀治疗2周后,A、B两组患者血清MMP-9和hs-CRP分别为(161.86±52.39)μg/L、(150.26±50.36)μg/L和(18.36±4.86)ng/ml和(15.61±4.53)ng/ml,均高于治疗前的(114.49±46.73)μg/L和(2.19±0.50)ng/ml(P<0.05),B组较A组改善更明显(P<0.05)。结论 ACS患者早期使用较大剂量瑞舒伐他汀可改善ACS患者预后。

Objective To explore the effects of rosuvastatin on serum matrix metalloproteinase-9（MMP-9）and hypersensitive C-reactive protein（hs-CRP）in the patients with acute coronary syndrome（ACS）.Methods A total of 60ACS patients was devided into groups of A（oral rosuvastatin10mg/d ly,30cases）,B（oral rosuvastatin 20mg/d,30cases）and C（controls,20cases）.Serum MMP-9and hs-CRP were detected by ELISA.Results Before treatment,levels of serum MMP-9and hs-CRP in groups of A and B were higher than those in group C（P〈0.05）.After treatment for two weeks,serum MMP-9and hs-CRP were（161.86±52.39）μg/L and（18.36±4.86）ng/ml in group A and（150.26±50.36）μg/L and（15.61±4.53）ng/ml in group B,which were significantly higher than（114.49±46.73）μg/L and（2.19±0.50）ng/ml before（P〈0.05）.The increases of MMP-9and hsCRP were more in group B than those in group A（P〈0.05）.Conclusion Early use of larger doses of rosuvastatin may improve the prognosis of patients with ACS.